Baseline patient characteristics
| Factor | Category | n=30 (%) |
| Age (median, range) | 64 (43–73) | |
| BMI (median, range) | 27 (19–33) | |
| Sex | Male | 14 (47) |
| Female | 16 (53) | |
| Smoking status* | Never | 1 (3) |
| Former | 12 (40) | |
| Current | 17 (57) | |
| AID | Yes | 2 (7) |
| No | 28 (93) | |
| ECOG | 0 | 18 (60) |
| 1 | 12 (40) | |
| T-stage | T3 | 11 (37) |
| T4 | 19 (63) | |
| N-stage | N0 | 18 (60) |
| N1 | 9 (30) | |
| N2 | 3 (10) | |
| Histology | Non-squamous | 21 (70) |
| Squamous | 8 (27) | |
| Melanoma lung metastasis | 1 (3) | |
| PD-L1 | 50% or above | 12 (40) |
| 1–49% | 3 (10) | |
| Less than 1% | 4 (13) | |
| Unknown | 11 (37) | |
| AGA | 0 | 28 (93) |
| 1 | 2 (7) | |
| Chemotherapy | 1 | 3 (10) |
| 2 | 26 (87) | |
| 3 | 1 (3) | |
| Immunotherapy | 1 | 4 (13) |
| 2 | 26 (87) | |
| Thoracic radiotherapy dose | 60 Gy | 3 (10) |
| 50 Gy | 25 (83) | |
| Less than 50 Gy | 2 (7) |
*Never smoker ≤100 cigarettes in a life-time, former=stopped smoking for >1 year, current=active smoker or has stopped for <1 year.
AGA, actionable genomic alteration; AID, autoimmune disease in medical history; BMI, body mass index; ECOG, performance status scale according to the Eastern Cooperative Oncology Group; PD-L1, programmed death ligand-1.